Pub Date : 2024-11-27DOI: 10.1038/s41585-024-00975-8
Anna Schueth
Everyone understands the tragedy of cancer; however, the severity of its effects are only known to those who have first-hand experience. Thus, not everyone understands how it feels to receive a diagnosis yourself or to support a loved one, or how colleagues and peers react at work and school. It begs the question: why are people who are dealing with a cancer diagnosis often still keeping it a secret?
I have spoken with many patients who were diagnosed with cancer during their childhood or as a teenager or young adult; in this scenario, the parents are responsible for bringing their children to a check-up in the hospital or their health practitioner, which also comes with a heavy emotional burden. A patient who recently finished her chemotherapy told me that she did not want to talk with high school friends about her diagnosis and that she would select carefully when and to whom she would open up about her cancer. People would react differently, ranging from overly friendly to avoiding the topic at all, meaning that it quickly became clear who her true friends were and who she could trust. Now that she has finished treatment, she still does not necessarily bring up the topic with new friends on her college campus. However, speaking with someone who is aware of how difficult life can be after cancer can enable her to understand her circumstances and support her during her studies, as college life can be hard on anyone, even those in perfect health.
{"title":"Opening up about cancer and mental health","authors":"Anna Schueth","doi":"10.1038/s41585-024-00975-8","DOIUrl":"https://doi.org/10.1038/s41585-024-00975-8","url":null,"abstract":"<p>Everyone understands the tragedy of cancer; however, the severity of its effects are only known to those who have first-hand experience. Thus, not everyone understands how it feels to receive a diagnosis yourself or to support a loved one, or how colleagues and peers react at work and school. It begs the question: why are people who are dealing with a cancer diagnosis often still keeping it a secret?</p><p>I have spoken with many patients who were diagnosed with cancer during their childhood or as a teenager or young adult; in this scenario, the parents are responsible for bringing their children to a check-up in the hospital or their health practitioner, which also comes with a heavy emotional burden. A patient who recently finished her chemotherapy told me that she did not want to talk with high school friends about her diagnosis and that she would select carefully when and to whom she would open up about her cancer. People would react differently, ranging from overly friendly to avoiding the topic at all, meaning that it quickly became clear who her true friends were and who she could trust. Now that she has finished treatment, she still does not necessarily bring up the topic with new friends on her college campus. However, speaking with someone who is aware of how difficult life can be after cancer can enable her to understand her circumstances and support her during her studies, as college life can be hard on anyone, even those in perfect health.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"257 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142718491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-20DOI: 10.1038/s41585-024-00963-y
Michael Leyderman, Thenappan Chandrasekar, Petros Grivas, Roger Li, Seetharam Bhat, Alina Basnet, Oleg Shapiro, Joseph Jacob, Michael A. Daneshvar, Eyal Kord, Gennady Bratslavsky, Hanan Goldberg
Non-muscle-invasive bladder cancer (NMIBC) is the most common type of bladder cancer presentation and is characterized by a varying probability of recurrence and progression. Sporadically, patients with NMIBC might also develop tumour metastases without any pathological evidence of muscle-invasive disease within the bladder, a condition known as metastatic NMIBC. In the published literature, this phenomenon is limited to several case reports and small reviews, with few data regarding the possible aetiologies. Several possible factors can be potentially associated with metastatic NMIBC, including tumour understaging, the number of transurethral resection procedures received by the patient, the presence of circulating tumour cells, the modality used for diagnostic cystoscopy and possible gender-associated differences. In this Perspective, our aim was to integrate and report currently available data on this relatively rare entity and provide some potential aetiological explanations.
{"title":"Metastasis development in non-muscle-invasive bladder cancer","authors":"Michael Leyderman, Thenappan Chandrasekar, Petros Grivas, Roger Li, Seetharam Bhat, Alina Basnet, Oleg Shapiro, Joseph Jacob, Michael A. Daneshvar, Eyal Kord, Gennady Bratslavsky, Hanan Goldberg","doi":"10.1038/s41585-024-00963-y","DOIUrl":"https://doi.org/10.1038/s41585-024-00963-y","url":null,"abstract":"<p>Non-muscle-invasive bladder cancer (NMIBC) is the most common type of bladder cancer presentation and is characterized by a varying probability of recurrence and progression. Sporadically, patients with NMIBC might also develop tumour metastases without any pathological evidence of muscle-invasive disease within the bladder, a condition known as metastatic NMIBC. In the published literature, this phenomenon is limited to several case reports and small reviews, with few data regarding the possible aetiologies. Several possible factors can be potentially associated with metastatic NMIBC, including tumour understaging, the number of transurethral resection procedures received by the patient, the presence of circulating tumour cells, the modality used for diagnostic cystoscopy and possible gender-associated differences. In this Perspective, our aim was to integrate and report currently available data on this relatively rare entity and provide some potential aetiological explanations.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"14 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-20DOI: 10.1038/s41585-024-00965-w
Kelvin Szolnoky, Tobias Nordström, Martin Eklund
Large language models are gaining increasing interest in the medical community; however, an important but overlooked aspect of their capacity is their ability to integrate with tools. This integration greatly extends their potential application in health care.
{"title":"Tomorrow’s patient management: LLMs empowered by external tools","authors":"Kelvin Szolnoky, Tobias Nordström, Martin Eklund","doi":"10.1038/s41585-024-00965-w","DOIUrl":"https://doi.org/10.1038/s41585-024-00965-w","url":null,"abstract":"Large language models are gaining increasing interest in the medical community; however, an important but overlooked aspect of their capacity is their ability to integrate with tools. This integration greatly extends their potential application in health care.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"197 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-14DOI: 10.1038/s41585-024-00961-0
Qi-Xiang Song, Sylvia O Suadicani, Hiromitsu Negoro, Hai-Hong Jiang, Rita Jabr, Christopher Fry, Wei Xue, Margot S Damaser
Increasing evidence suggested the multifactorial nature of nocturia, but the true pathogenesis of this condition still remains to be elucidated. Contemporary clinical medications are mostly symptom based, aimed at either reducing nocturnal urine volume or targeting autonomic receptors within the bladder to facilitate urine storage. The day-night switch of the micturition pattern is controlled by circadian clocks located both in the central nervous system and in the peripheral organs. Arousal threshold and secretion of melatonin and vasopressin increase at night-time to achieve high-quality sleep and minimize nocturnal urine production. In response to the increased vasopressin, the kidney reduces the glomerular filtration rate and facilitates the reabsorption of water. Synchronously, in the bladder, circadian oscillation of crucial molecules occurs to reduce afferent sensory input and maintain sufficient bladder capacity during the night sleep period. Thus, nocturia might occur as a result of desynchronization in one or more of these circadian regulatory mechanisms. Disrupted rhythmicity of the central nervous system, kidney and bladder (known as the brain-kidney-bladder circadian axis) contributes to the pathogenesis of nocturia. Novel insights into the chronobiological nature of nocturia will be crucial to promote a revolutionary shift towards effective therapeutics targeting the realignment of the circadian rhythm.
{"title":"Disruption of circadian rhythm as a potential pathogenesis of nocturia.","authors":"Qi-Xiang Song, Sylvia O Suadicani, Hiromitsu Negoro, Hai-Hong Jiang, Rita Jabr, Christopher Fry, Wei Xue, Margot S Damaser","doi":"10.1038/s41585-024-00961-0","DOIUrl":"10.1038/s41585-024-00961-0","url":null,"abstract":"<p><p>Increasing evidence suggested the multifactorial nature of nocturia, but the true pathogenesis of this condition still remains to be elucidated. Contemporary clinical medications are mostly symptom based, aimed at either reducing nocturnal urine volume or targeting autonomic receptors within the bladder to facilitate urine storage. The day-night switch of the micturition pattern is controlled by circadian clocks located both in the central nervous system and in the peripheral organs. Arousal threshold and secretion of melatonin and vasopressin increase at night-time to achieve high-quality sleep and minimize nocturnal urine production. In response to the increased vasopressin, the kidney reduces the glomerular filtration rate and facilitates the reabsorption of water. Synchronously, in the bladder, circadian oscillation of crucial molecules occurs to reduce afferent sensory input and maintain sufficient bladder capacity during the night sleep period. Thus, nocturia might occur as a result of desynchronization in one or more of these circadian regulatory mechanisms. Disrupted rhythmicity of the central nervous system, kidney and bladder (known as the brain-kidney-bladder circadian axis) contributes to the pathogenesis of nocturia. Novel insights into the chronobiological nature of nocturia will be crucial to promote a revolutionary shift towards effective therapeutics targeting the realignment of the circadian rhythm.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":12.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-14DOI: 10.1038/s41585-024-00953-0
Pedro F. S. Freitas, Alireza Abdshah, Rana R. McKay, Nima Sharifi
Androgen receptor stimulation by testosterone and dihydrotestosterone is crucial for prostate cancer progression. Despite the initial effectiveness of androgen deprivation therapy (ADT), castration-resistant prostate cancer eventually develops in most men. A common germline missense-encoding polymorphism in HSD3B1 increases extra-gonadal androgen biosynthesis from adrenal precursors owing to increased availability of the encoded enzyme 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) — hence, it is called the adrenal-permissive enzyme. This mechanism explains the more rapid progression to castration-resistant prostate cancer in men who inherit this allele than in men without it via sustained androgen receptor activation despite ADT. Multiple clinical studies, including data derived from prospective phase III studies, have linked adrenal-permissive allele inheritance to inferior clinical responses to ADT and increased mortality, but reversal is possible with upfront adrenal androgen blockade. The adrenal-permissive allele exhibits divergent frequencies across various groups worldwide, which could contribute to differences in clinical outcomes among these populations. Large-scale data from the Million Veteran Program have shown homozygous HSD3B1 adrenal-permissive allele inheritance to be an independent biomarker of prostate cancer-specific mortality. Together, these observations support the integration of HSD3B1 into germline testing and clinical trials as it might help to identify groups at increased likelihood of benefiting from early, intensified, AR-targeting interventions. Lastly, 3βHSD1 is a promising target for pharmacological inhibition, which enables new strategies for systemic prostate cancer therapy.
{"title":"HSD3B1, prostate cancer mortality and modifiable outcomes","authors":"Pedro F. S. Freitas, Alireza Abdshah, Rana R. McKay, Nima Sharifi","doi":"10.1038/s41585-024-00953-0","DOIUrl":"https://doi.org/10.1038/s41585-024-00953-0","url":null,"abstract":"<p>Androgen receptor stimulation by testosterone and dihydrotestosterone is crucial for prostate cancer progression. Despite the initial effectiveness of androgen deprivation therapy (ADT), castration-resistant prostate cancer eventually develops in most men. A common germline missense-encoding polymorphism in <i>HSD3B1</i> increases extra-gonadal androgen biosynthesis from adrenal precursors owing to increased availability of the encoded enzyme 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) — hence, it is called the adrenal-permissive enzyme. This mechanism explains the more rapid progression to castration-resistant prostate cancer in men who inherit this allele than in men without it via sustained androgen receptor activation despite ADT. Multiple clinical studies, including data derived from prospective phase III studies, have linked adrenal-permissive allele inheritance to inferior clinical responses to ADT and increased mortality, but reversal is possible with upfront adrenal androgen blockade. The adrenal-permissive allele exhibits divergent frequencies across various groups worldwide, which could contribute to differences in clinical outcomes among these populations. Large-scale data from the Million Veteran Program have shown homozygous <i>HSD3B1</i> adrenal-permissive allele inheritance to be an independent biomarker of prostate cancer-specific mortality. Together, these observations support the integration of <i>HSD3B1</i> into germline testing and clinical trials as it might help to identify groups at increased likelihood of benefiting from early, intensified, AR-targeting interventions. Lastly, 3βHSD1 is a promising target for pharmacological inhibition, which enables new strategies for systemic prostate cancer therapy.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"72 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142610398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The clinical diagnosis of renal cell carcinoma (RCC) is constantly evolving. Diagnostic imaging of RCC relying on enhanced computed tomography (CT) and magnetic resonance imaging (MRI) is commonly used for renal mass characterization and assessment of tumour thrombosis, whereas pathology is the gold standard for establishing diagnosis. However, molecular imaging is rapidly improving the clinical management of RCC, particularly clear-cell RCC. Molecular imaging aids in the non-invasive visualization and characterization of specific biomarkers such as carbonic anhydrase IX and CD70 within the tumours, which help to assess tumour heterogeneity and status. Target-specific molecular imaging of RCCs will substantially improve the diagnostic landscape of RCC and will further facilitate clinical decision-making regarding initial staging and re-staging, monitoring of recurrence and metastasis, patient stratification and selection, and the prediction and evaluation of treatment responses.
肾细胞癌(RCC)的临床诊断在不断发展。依靠增强计算机断层扫描(CT)和磁共振成像(MRI)进行的 RCC 诊断成像常用于肾肿块特征描述和肿瘤血栓形成评估,而病理学则是确诊的金标准。然而,分子成像技术正在迅速改善 RCC,尤其是透明细胞 RCC 的临床治疗。分子成像有助于对肿瘤内的碳酸酐酶 IX 和 CD70 等特定生物标记物进行无创观察和定性,这有助于评估肿瘤的异质性和状态。RCC的靶向特异性分子成像将大大改善RCC的诊断状况,并将进一步促进有关初始分期和再分期、复发和转移监测、患者分层和选择以及治疗反应预测和评估的临床决策。
{"title":"Molecular imaging of renal cell carcinomas: ready for prime time.","authors":"Qianyun Wu, Hongda Shao, Wei Zhai, Gang Huang, Jianjun Liu, Jeremie Calais, Weijun Wei","doi":"10.1038/s41585-024-00962-z","DOIUrl":"https://doi.org/10.1038/s41585-024-00962-z","url":null,"abstract":"<p><p>The clinical diagnosis of renal cell carcinoma (RCC) is constantly evolving. Diagnostic imaging of RCC relying on enhanced computed tomography (CT) and magnetic resonance imaging (MRI) is commonly used for renal mass characterization and assessment of tumour thrombosis, whereas pathology is the gold standard for establishing diagnosis. However, molecular imaging is rapidly improving the clinical management of RCC, particularly clear-cell RCC. Molecular imaging aids in the non-invasive visualization and characterization of specific biomarkers such as carbonic anhydrase IX and CD70 within the tumours, which help to assess tumour heterogeneity and status. Target-specific molecular imaging of RCCs will substantially improve the diagnostic landscape of RCC and will further facilitate clinical decision-making regarding initial staging and re-staging, monitoring of recurrence and metastasis, patient stratification and selection, and the prediction and evaluation of treatment responses.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":12.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-11DOI: 10.1038/s41585-024-00952-1
Tania E. Saez Lancellotti, María V. Avena, Abi K. Funes, María-Rosa Bernal-López, Ricardo Gómez-Huelgas, Miguel W. Fornes
The decline in male fertility correlates with the global rise in obesity and dyslipidaemia, representing significant public health challenges. High-fat diets induce metabolic alterations, including hypercholesterolaemia, hepatic steatosis and atherosclerosis, with detrimental effects on testicular function. Testicular tissue, critically dependent on lipids for steroidogenesis, is particularly vulnerable to these metabolic disruptions. Excessive lipid accumulation within the testes, including cholesterol, triglycerides and specific fatty acids, disrupts essential sperm production processes such as membrane formation, maturation, energy metabolism and cell signalling. This leads to apoptosis, impaired spermatogenesis, and abnormal sperm morphology and function, ultimately compromising male fertility. During spermiogenesis, round spermatids undergo extensive reorganization, including the formation of the acrosome, manchette and specialized filamentous structures, which are essential for defining the final sperm cell shape. In this Perspective, we examine the impact of high-fat diets on the cytoskeleton of spermatogenic cells and its consequences to identify the mechanisms underlying male infertility associated with dyslipidaemia. Understanding these processes may facilitate the development of therapeutic strategies, such as dietary interventions or natural product supplementation, that aim to address infertility in men with obesity and hypercholesterolaemia. The investigation of cytoskeleton response to lipid stress extends beyond male reproduction, offering insights with broader implications.
{"title":"Exploring the impact of lipid stress on sperm cytoskeleton: insights and prospects","authors":"Tania E. Saez Lancellotti, María V. Avena, Abi K. Funes, María-Rosa Bernal-López, Ricardo Gómez-Huelgas, Miguel W. Fornes","doi":"10.1038/s41585-024-00952-1","DOIUrl":"https://doi.org/10.1038/s41585-024-00952-1","url":null,"abstract":"<p>The decline in male fertility correlates with the global rise in obesity and dyslipidaemia, representing significant public health challenges. High-fat diets induce metabolic alterations, including hypercholesterolaemia, hepatic steatosis and atherosclerosis, with detrimental effects on testicular function. Testicular tissue, critically dependent on lipids for steroidogenesis, is particularly vulnerable to these metabolic disruptions. Excessive lipid accumulation within the testes, including cholesterol, triglycerides and specific fatty acids, disrupts essential sperm production processes such as membrane formation, maturation, energy metabolism and cell signalling. This leads to apoptosis, impaired spermatogenesis, and abnormal sperm morphology and function, ultimately compromising male fertility. During spermiogenesis, round spermatids undergo extensive reorganization, including the formation of the acrosome, manchette and specialized filamentous structures, which are essential for defining the final sperm cell shape. In this Perspective, we examine the impact of high-fat diets on the cytoskeleton of spermatogenic cells and its consequences to identify the mechanisms underlying male infertility associated with dyslipidaemia. Understanding these processes may facilitate the development of therapeutic strategies, such as dietary interventions or natural product supplementation, that aim to address infertility in men with obesity and hypercholesterolaemia. The investigation of cytoskeleton response to lipid stress extends beyond male reproduction, offering insights with broader implications.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":"11 1","pages":""},"PeriodicalIF":15.3,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}